Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05440760 · ClinicalTrials.gov registry record · NA
Using Virtual Reality Technology to Improve Patient Experience and Quality of Care During Brachytherapy
A NA study of Endocervical Cancer, sponsored by University of Arkansas.
- Recruiting
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT05440760: Recruiting NA study of Endocervical Cancer, sponsored by University of Arkansas.
NCT05440760 is a NA study of Endocervical Cancer that is actively recruiting participants, run by University of Arkansas. The registered enrollment target is 20 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05440760, a NA study of Endocervical Cancer, is actively recruiting participants, sponsored by University of Arkansas.
- RECRUITING
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective is to demonstrate the feasibility of incorporating VR distraction into the brachytherapy and radiotherapy clinical workflow. The secondary objective is to determine if VR distraction during brachytherapy treatment for cervical cancer improves subjects' satisfaction, procedural/acute pain, and need for analgesics or anxiolytics.
Conditions Studied
Interventions
- DEVICE The Oculus Quest 2 Virtual Reality Headset
Study Locations (1)
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2022-08-08 |
| Est. Completion | 2027-12 |
| Phase | NA |
What NCT05440760 shows while recruiting
NCT05440760 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Endocervical Cancer appearing as the primary indexed condition, and to 1 intervention - of which The Oculus Quest 2 Virtual Reality Headset is the first listed.
NCT05440760 reports a single indexed study location in Arkansas.
Frequently Asked Questions
What is clinical trial NCT05440760 about?
NCT05440760 is a clinical study titled "Using Virtual Reality Technology to Improve Patient Experience and Quality of Care During Brachytherapy". The primary objective is to demonstrate the feasibility of incorporating VR distraction into the brachytherapy and radiotherapy clinical workflow. The secondary objective is to determine if VR distraction during brachytherapy treatment for cervical cancer improves subjects' satisfaction, procedural...
What is the current status of trial NCT05440760?
This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2022-08-08. Estimated completion is 2027-12.
What conditions does trial NCT05440760 study?
This clinical trial studies the following conditions: Endocervical Cancer.
What interventions are being tested in trial NCT05440760?
The interventions under investigation include: The Oculus Quest 2 Virtual Reality Headset (DEVICE).
Who is sponsoring clinical trial NCT05440760?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05440760 being conducted?
This trial has 1 study location across Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endocervical Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05440760's enrollment target sits among peer trials
20 1768th of 2000 higher than 140 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI